TP53 and breast carcinoma: This is also consistent with colony forming assays which showed that long‐term palbociclib treatment reduces proliferative potential in breast cancer lines, but this inhibition was less pronounced than in RPE1 cells, and it was not markedly affected by p53 status (Fig 6F).